IgA EGFR antibodies mediate tumour killing in vivo (pages 1213–1226)
Peter Boross, Stefan Lohse, Maaike Nederend, Johannes Hendrik Marco Jansen, Geert van Tetering, Michael Dechant, Matthias Peipp, Louise Royle, Li Phing Liew, Louis Boon, Nico van Rooijen, Wim K. Bleeker, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius and Jeanette H. W. Leusen
Article first published online: 5 AUG 2013 | DOI: 10.1002/emmm.201201929
The study reveals that IgA antibodies directed against EGFR and engaging Fcalpha receptor (FcαRI) on effector cells, have in vivo anti-cancer activity. These data support the development of novel immunotherapeutic strategies based on targeting FcαRI.